LPAR6 Inhibits the Progression of Hepatocellular Carcinoma (HCC) by Suppressing the Nuclear Translocation of YAP/TAZ
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26094205 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Gegentuya Bao und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Inner Mongolia University, Hohhot 010110, China. Hauptthemen laut MEDLINE: Receptors, Lysophosphatidic Acid, Carcinoma, Hepatocellular, Liver Neoplasms, Adaptor Proteins, Signal Transducing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Lysophosphatidic acid (LPA), a key bioactive lipid, modulates cellular functions through interactions with LPA receptors (LPAR1-6) of the G protein-coupled receptor (GPCR) family, participating in both physiological and pathological processes. While LPA/LPAR signaling typically promotes cancer progression by regulating angiogenesis and cancer cell metastasis, our study unexpectedly reveals that LPA exhibits an inhibitory effect on cellular activity in hepatocellular carcinoma (HCC). We further investigate the specific receptor subtypes mediating these effects and elucidate the underlying mechanisms at the cellular, tissue, and organismal levels. Pharmacological studies demonstrated that LPA predominantly inhibits HCC progression through activation of LPAR6. Mechanistically, LPA/LPAR6 activation suppresses HCC proliferation, migration, and epithelial–mesenchymal transition (EMT). In vivo, LPAR6 overexpression in a nude mouse xenograft model significantly reduced tumor growth rate and volume, accompanied by decreased Ki-67 expression in tumor tissues, as shown by immunohistochemical analysis. Transcriptomic analysis combined with Western blot experiments demonstrated that LPA/LPAR6 inhibits YAP/TAZ nuclear translocation, thereby suppressing HCC cell proliferation and migration. In conclusion, these findings suggest that enhancing LPAR6 expression or developing LPAR6 agonists may offer a promising therapeutic strategy for adjuvant cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Inner Mongolia University, Hohhot 010110, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Bao, G., Zhai, M., Yan, Y., Wang, Y., & Damirin, A. (2025). LPAR6 Inhibits the Progression of Hepatocellular Carcinoma (HCC) by Suppressing the Nuclear Translocation of YAP/TAZ. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26094205
Vancouver
Bao G, Zhai M, Yan Y, Wang Y, Damirin A. LPAR6 Inhibits the Progression of Hepatocellular Carcinoma (HCC) by Suppressing the Nuclear Translocation of YAP/TAZ. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26094205
BibTeX
@article{Bao2025,
author = {Bao, Gegentuya and Zhai, Manjue and Yan, Yali and Wang, Yuewu and Damirin, Alatangaole},
title = {LPAR6 Inhibits the Progression of Hepatocellular Carcinoma (HCC) by Suppressing the Nuclear Translocation of YAP/TAZ},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26094205}
}
EUVIMED